0001209191-21-045691.txt : 20210706 0001209191-21-045691.hdr.sgml : 20210706 20210706200026 ACCESSION NUMBER: 0001209191-21-045691 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210701 FILED AS OF DATE: 20210706 DATE AS OF CHANGE: 20210706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crystal Adam CENTRAL INDEX KEY: 0001825445 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 211075918 MAIL ADDRESS: STREET 1: C4 THERAPEUTICS, INC. STREET 2: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-01 0 0001662579 C4 Therapeutics, Inc. CCCC 0001825445 Crystal Adam C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #200 WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer Common Stock 2021-07-01 4 M 0 15000 6.50 A 15000 D Common Stock 2021-07-01 4 S 0 13300 37.9263 D 1700 D Common Stock 2021-07-01 4 S 0 1700 38.38 D 0 D Stock Option (Right to Buy) 6.50 2021-07-01 4 M 0 15000 0.00 D 2029-04-08 Common Stock 15000 142292 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. /s/ Shoaib Ghias, Attorney-in-Fact 2021-07-06